Genmab A/S (NASDAQ:GMAB) Lowered to "Hold" Rating by Zacks Research

Key Points

• Genmab A/S has been downgraded by Zacks Research from a "strong-buy" to a "hold" rating, reflecting a shift in analyst sentiment.
• Despite the downgrade, other analysts such as Truist Financial and HC Wainwright maintain a "buy" rating with price target increases, suggesting mixed opinions on the stock's future performance.
• The company's stock saw a modest increase of 1.0% on the day, with a current market cap of $15.44 billion and an average price target of $37.60.

Zacks Research cut shares of Genmab A/S (NASDAQ:GMAB - Free Report) from a strong-buy rating to a hold rating in a report released on Tuesday, August 19th,Zacks.com reports.

Several other analysts have also issued reports on GMAB. Wall Street Zen raised Genmab A/S from a "hold" rating to a "buy" rating in a report on Monday, July 28th. Truist Financial upped their price objective on Genmab A/S from $45.00 to $46.00 and gave the stock a "buy" rating in a research note on Tuesday, July 8th. Finally, HC Wainwright boosted their target price on Genmab A/S from $35.00 to $36.00 and gave the stock a "buy" rating in a research report on Friday, August 15th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Genmab A/S presently has an average rating of "Moderate Buy" and an average target price of $37.60.

Genmab A/S Trading Up 0.8%

NASDAQ:GMAB traded up $0.18 during trading hours on Tuesday, reaching $24.49. 591,592 shares of the company traded hands, compared to its average volume of 1,434,001. The business's 50-day moving average price is $21.96 and its two-hundred day moving average price is $21.14. The stock has a market capitalization of $15.71 billion, a P/E ratio of 12.30, a P/E/G ratio of 7.15 and a beta of 0.95. Genmab A/S has a 1 year low of $17.24 and a 1 year high of $27.94.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.39 by $0.15. The firm had revenue of $925.00 million during the quarter, compared to analysts' expectations of $5.77 billion. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%. Genmab A/S has set its FY 2025 guidance at EPS. As a group, equities analysts anticipate that Genmab A/S will post 1.45 EPS for the current year.

Institutional Investors Weigh In On Genmab A/S

Hedge funds and other institutional investors have recently modified their holdings of the business. Headlands Technologies LLC raised its holdings in shares of Genmab A/S by 1,525.0% in the first quarter. Headlands Technologies LLC now owns 1,560 shares of the company's stock worth $31,000 after buying an additional 1,464 shares during the period. CWM LLC raised its holdings in shares of Genmab A/S by 50.5% in the second quarter. CWM LLC now owns 1,797 shares of the company's stock worth $37,000 after buying an additional 603 shares during the period. Caitong International Asset Management Co. Ltd raised its holdings in shares of Genmab A/S by 124.3% in the first quarter. Caitong International Asset Management Co. Ltd now owns 1,931 shares of the company's stock worth $38,000 after buying an additional 1,070 shares during the period. AlphaCore Capital LLC bought a new position in Genmab A/S in the second quarter worth approximately $44,000. Finally, EverSource Wealth Advisors LLC grew its stake in Genmab A/S by 124.9% in the second quarter. EverSource Wealth Advisors LLC now owns 2,114 shares of the company's stock worth $44,000 after purchasing an additional 1,174 shares in the last quarter. 7.07% of the stock is currently owned by hedge funds and other institutional investors.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.